GlassScriptPhysician profile
Carl J Carlson
NPI 1386669489
$10,373.68
in general payments reported to CMS, 2019-2025
43 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,333 · 2020: $1,121 · 2021: $1,443 · 2022: $1,884 · 2023: $1,378 · 2024: $1,116 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,477 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,476.79 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,488.04 | 2019-2025 | Repatha, Repatha, Enbrel |
| Actelion Pharmaceuticals US, INC. | $1,208.97 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $795.43 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $751.98 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $745.51 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $709.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $654.71 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $652.68 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $504.57 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $304.91 | 2022-2025 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $258.53 | 2019-2023 | |
| Novo Nordisk INC | $252.58 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $172.10 | 2019 | |
| Abbott Laboratories | $155.26 | 2021-2022 | |
| Esperion Therapeutics, INC. | $150.84 | 2020-2024 | Nexletol |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.